期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

DEK的表达与结直肠癌患者预后的相关性研究 被引量：2

Expression and prognostic significance of DEK in human colorectal carcinoma
下载PDF
导出
摘要 目的:采用免疫组化技术,分析DEK基因在结直肠癌患者中的表达情况及其与预后的相关性。方法:运用免疫组化SP法,检测DEK基因在169例结直肠癌患者肿瘤组织及癌旁组织中的表达情况,并运用统计分析软件分析DEK表达水平与结直肠癌患者预后的相关性。结果:DEK的表达率在结直肠癌组织(85/169,50.30%)明显高于癌旁正常组织(28/169,16.57%),差异具有统计学意义(P<0.01)。DEK在肿瘤组织中的表达情况与病人年龄、性别、肿瘤分化程度、TNM分期及肿瘤大小等因素无相关性,与总生存率(OS)显著相关(P<0.05)。结论:DEK表达水平与结直肠癌预后密切相关,DEK高表达的结直肠癌患者预后较差。 Objective ：To analyze DEK gene expression and prognostic significance in human colorectal carcinoma by using immunohistochemical techniques. Methods ：Immunohistochemical SP method was used to test the expression of DEK gene in 169 eases of colorectal cancer tissue and para - carcinoma tissue, and statistical analysis software was used to analyze the correlation between DEK gene expression and prognostic significance in human colorectal carcino- ma. Results：The expression rate of DEK in colorectal cancer tissue 85/169 （50.30%） was significantly higher than those in para - carcinoma tissue,28/169 （ 16.57% ） （ P 〈 0.01 ）. The level of DEK expression in the tumor tissues was irrelevant to age, gender, differentiated degree, TNM stage and location, but significantly correlated with overall survival（OS） （ P 〈 0.05 ）. Conclusion： DEK expression is closely related to the prognosis of colorectal cancer. There will be poor prognosis for colorectal cancer patients with high DEK expression.
作者 张坤 杨静 宋扬 赵鹏 苏海川 冯英明
机构地区 第四军医大学唐都医院肿瘤科
出处 《现代肿瘤医学》 CAS 2014年第4期875-878,共4页 Journal of Modern Oncology
关键词 DEK 结直肠癌 免疫组化 生存分析 DEK colorectal cancer immunohistochemical survival analysis
分类号 R735.35 [医药卫生—肿瘤] R735.37 [医药卫生—肿瘤]
  • 相关文献

参考文献19

  • 1Wise-Draper TM,Mintz-Cole RA,Morris TA,et al.Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo[J].Cancer Res,2009,69 (5):1792-1799.
  • 2Wu Q,Li Z,Lin H,et al.DEK overexpression in uterine cervical cancers[J].Pathol Int,2008,58 (6):378-382.
  • 3Orlic M,Spencer CE,Wang L,et al.Expression analysis of 6p22 genomic gain in retinoblastoma[J].Genes Chromosomes Cancer,2006,45 (1):72-82.
  • 4Carro MS,Spiga FM,Quarto M,et al.DEK expression is controlled by E2F and deregulated in diverse tumor types[J].Cell Cycle,2006,5 (11):1202-1207.
  • 5Sanchez-Carbayo M,Socci ND,Lozano JJ,et al.Gene discovery in bladder cancer progression using cDNA microarrays[J].Am J Pathol,2003,163(2):505-516.
  • 6Larramendy ML,Niini T,Elonen E,et al.Overexpression of translocation-associated fusion genes of FGFRI,MYC,NPMI,and DEK,but absence of the translocations in acute myeloid leukemia.A microarray analysis[J].Haematologica,2002,87 (6):569-577.
  • 7Kroes RA,Jastrow A,McLone MG,et al.The identification of novel therapeutic targets for the treatment of malignant brain tumors[J].Cancer Lett,2000,156 (2):191-198.
  • 8Grottke C,Mantwill K,Dietel M,et al.Identification of differentially expressed genes in human melanoma cells with acquired resistance to various antineoplastic drugs[J].Int J Cancer,2000,88 (4):535-546.
  • 9Kondoh N,Wakatsuki T,Ryo A,et al.Identification and characterization of genes associated with human hepatocellular carcinogenesis[J].Cancer Res,1999,59(19):4990-4996.
  • 10Friedrichs K,Gluba S,Eidtmann H,et al.Overexpression of p53 and prognosis in breast cancer[J].Cancer,1993,72:3641-3647.

二级参考文献20

  • 1Tournigand C,Andre T,Achille E,et al.FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer:a randomized GERCOR study[J].J Clin Oncol,2004,22:229 -237.
  • 2Xiong HQ,Ajani JA.Treatment of colorectal cancer metastasis:the role of chemotherapy [J].Cancer Metastasis Rev,2004,23(1 -2):145 -163.
  • 3Kohne CH,van Cutsem E,Wils J,Bokemeyer C,et al.Phase Ⅲ study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer:European Organization for Research and Treatment of Cancer Gastrointestinal Group Study 40986 [J].J Clin Oncol.2005,23 (22) :4856 - 4865.
  • 4Martin MJ.Current stage-specific chemotherapeutic options in colon cancer [J].Expert Rev Anticancer Ther,2005,5 (4):695 -704.
  • 5Grothey A,Deschler B,Kroening H,et al.Phase Ⅲ study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA)(FOLFOX) in advanced colorectal cancer (ACRC) [J].Proc Am Soc Clin Oncol,2002,21 :abstr 512.
  • 6Kohne CH,Cutsem VE.Wils JA et al.Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer:Results of EORTC GI Group study 40986 [J].Proc Am Soc Clin Oncol,2004,23:abstr 1018.
  • 7Saltz LB,Cox JV,Blanke C,et al.Irinotecan plus fluorouracil and leucovorin for metastatic Colorectal cancer.Irinotecan Study Group[J].N Engl J Med,2000,343(13) :905 -914.
  • 8de Gramont A,Figer A,Seymour M,et al.Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer[J].J Clin Oncol,2000,18(16) :2938- 2947.
  • 9de Gramont A,Bosset JF,Milan C,et al.Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer:a French intergroup study[J].J Clin Oncol ,1997,15(2) :808 -815.
  • 10Cunningham D,Humblet Y,Siena S,et al.Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer[J].N Engl J Med,2004,351 (4) :337- 345.

共引文献5

同被引文献29

  • 1吕自力,文剑明,罗殿中,张文敏,肖刚,张萌.肿瘤相关基因在肝细胞癌及癌旁正常肝组织中表达[J].临床与实验病理学杂志,2004,20(6):654-658. 被引量：4
  • 2汪亚伦,王彤,许凤,冮岩,王杰.伴有6;9染色体易位急性髓系白血病患者DEK-CAN融合基因表达分析[J].中国实验血液学杂志,2006,14(2):232-236. 被引量：8
  • 3Kappes F,Scholten I ,Richter N,et al. Functional do- mains of the ubiquitous chromatin protein DEK[J]. Mol Cell Biol, 2004, 24(13):6 000-6 010.
  • 4Aravind L, Koonin EV. SAP-a putative DNA-hinding motif involved in chromosomai organization[J]. Trends Biochem Sci,2000,25(3) :112-114.
  • 5Waldmann T,Baack M,Richter N,et al. Structure-spe- cific binding of the protooncogene protein DEK to DNA [J]. Nucleic Acids RES, 2003, 31(23):7 003-7 010.
  • 6Alexiadis V, Waldmann T, Andersen J, et al. The pro- tein encoded by the proto-oncogene DEK changes the topology of chromatin and reduces the efficiency of DNA replication in a chromatin-specific manner[J]. Genes Dev,2000,14(ll) :1 308-1 312.
  • 7Wise-Draper TM, Mintz Colr RA, Morris TA, et al. Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo[J]. Cancer Res,2009,69(5):1 792-1 799.
  • 8Wise-Draper TM, Allen HV, Jones EE, et al. Apop- tosis inhibition by the human DEK oncoprotein involves interference with P53 functions[J]. Mol Cell Biol, 2006, 26(20) :7 506-7 519.
  • 9Secchiero P, Voltan R, Iasio MG, et al. The oncogene DEK promotes leukemic cell survival and is downregu lated by both Nutlin-3 and chlorambucil in B-chronic lymphocytic leukemic cells[J]. Clin Cancer Res,2010, 16(6):1 824-1 833.
  • 10Lee KS, Kim DW, Kim JY, et al. Caspase-dependent apoptosis induction by targeted expression of DEK in- drosophila involves histone acetylation inhibition[J]. J Cell Bioche,2008,1(103) :1 283-1 293.

引证文献2

二级引证文献1

现代肿瘤医学
2014年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部